People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
WeightWatchers said Tuesday it is filing for Chapter 11 bankruptcy protection to eliminate US$1.15 billion in debt and focus on its transition into a telehealth services provider.
Novo Nordisk announces Health Canada has granted priority review status for once-weekly semaglutide to treat metabolic dysfunction-associated steatohepatitis.
To coincide with the release on Canada’s new guidelines for obesity in children, Obesity Canada is offering a new free introductory course on pediatric obesity care.
‘The first thing a physician does is weigh children and adolescents and plot their growth on a growth chart. That is a brilliant but often missed opportunity to simply ask a child or adolescent ‘How do you feel about your weight?’’
